
    
      This is a 7-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled,
      parallel group design study in male and female subjects with schizophrenia who are stabilised
      on antipsychotic medication. Subjects will be randomised to receive either GSK239512 or
      placebo for 7 weeks. They will undergo weekly review of safety, tolerability and cognitive
      performance measures.
    
  